Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Non-Current Assets (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Other Non-Current Assets data on record, last reported at $5.0 million in Q2 2025.

  • For Q2 2025, Other Non-Current Assets rose 1.73% year-over-year to $5.0 million; the TTM value through Jun 2025 reached $5.0 million, up 1.73%, while the annual FY2024 figure was $115000.0, 67.33% down from the prior year.
  • Other Non-Current Assets reached $5.0 million in Q2 2025 per GLUE's latest filing, up from $4.9 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.3 million in Q1 2023 and bottomed at $115000.0 in Q4 2024.
  • Average Other Non-Current Assets over 3 years is $3.4 million, with a median of $4.9 million recorded in 2024.
  • The widest YoY moves for Other Non-Current Assets: up 1572.16% in 2024, down 67.33% in 2024.
  • A 3-year view of Other Non-Current Assets shows it stood at $352000.0 in 2023, then tumbled by 67.33% to $115000.0 in 2024, then soared by 4204.35% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $5.0 million in Q2 2025, $4.9 million in Q1 2025, and $115000.0 in Q4 2024.